11/03/2024 - Covid-19
This is revealed by a study at Hospital del Mar, which prospectively analyzed data from nearly 2,000 people followed at the center's Post-COVID Unit. The main risk factors for developing persistent COVID are obesity, asthma and the severity of the disease. Women are also at higher risk These results lead the authors of the study to consider antiviral treatment also for people with SARS-CoV-2 infection who meet these risk factors, even if they do not suffer from severe COVID.
Més informació "Treatment of COVID-19 with antivirals may protect from persistent COVID"
28/02/2024 - Covid-19
One of them is related to heart disease, according to the CARGENCORS study. The work has allowed finding a significant association of new genetic variants previously related to heart disease, thrombosis, inflammation, with the severity of COVID-19 in more than 3000 COVID-19 patients in the area of Barcelona and Girona. People with these variants have a 10-60% increased chance of developing severe disease. The CARGENCORS (CARdiovascular GENEtic risk score for Risk Stratification of patients positive for SARS-CoV-2 (COVID-19) virus) study has established a direct link between some of the genetic factors that increase the risk of heart disease and the severity of COVID-19. The work, published in the Journal of Medical Virology, marks a further step towards understanding the mechanisms of COVID-19 severity through susceptibility in heart disease.
Més informació "New genetic variants related to severe COVID-19 identified"
14/02/2024 - Covid-19
It is a monoclonal antibody with prophylactic and therapeutic action, isolated from blood samples of a patient infected by SARS-CoV-2 during the first wave of the pandemic. The antibody has been designed and developed by researchers from the Hospital del Mar Research Institute, the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology and the Center for Genomic Regulation. In addition, this new treatment has been patented pending commercial development. This new treatment has been patented pending commercial development. The results of the work have been published in the journal Nature Communications.
Més informació "New antibody blocks all SARS-CoV-2 variants in preclinical models"
07/09/2023 - Covid-19
Overall, health has worsened across the population, especially regarding anxiety and depression, as well as pain and discomfort. But the effects of the pandemic have hit educated women especially hard, narrowing their health disparities with population groups with a lower education after initial home confinement. The researchers attribute this development to the negative effect of teleworking on the health of people who worked from home and had to care for family members. At the same time, there may have been a positive effect of government measures to mitigate the economic impact of the pandemic among more disadvantaged groups. The work is part of the MINDCOVID project, and was based on telephone interview surveys of 2,000 people. It is published in the International Journal for Equity in Health.
Més informació "COVID-19 has reduced health inequalities in Spain"
27/10/2022 - Covid-19
A study by the Hospital del Mar Medical Research Institute and Pompeu Fabra University has found that not all HIV patients respond adequately to the SARS-CoV-2 vaccine. The work has been published in the journal Frontiers in Immunology. Up to 20% of people with HIV being treated with antiretroviral drugs do not regain normal levels of immune cells in their blood. These people, with a depressed immune system, are considered to be at risk of SARS-CoV-2 infection and were prioritised in the COVID-19 vaccination strategy, just as other at-risk groups were. However, until now it was not known how they responded to immunisation with RNA-based vaccines, such as those from Pfizer and BioNTech.
04/07/2022 - Covid-19
The possibility of re-freezing vials once they are prepared may enable the manipulation of vaccines in the country of origin, freezing the syringes, and sending them to their destination for immediate use, without the need for a major infrastructure. The shelf life of the re-frozen vaccine is at least one month.
07/07/2022 - Covid-19
A study on the vaccine response of patients with primary antibody deficiency carried out by the Functional Unit of Primary Immunodeficiencies at Hospital del Mar together with the dibi Network (Reference Laboratory of Catalonia) has revealed that a good number of these people have antibodies against SARS-CoV-2 without actually having contracted COVID-19. The study, published in the journal Immunology, is the first to certify the transmission of antinucleocapsid antibodies (ANC) from donors to patients with primary immunodeficiency.
18/05/2022 - Covid-19
A study by doctors and researchers at Hospital del Mar and the Hospital del Mar Medical Research Institute confirms that COVID-19 infection is much more virulent than the flu in this group of patients, despite the fact that they are younger and in better health. They also require longer hospital stays and more care. This means that the price of their treatment is double that of patients admitted for influenza, with an extra cost of almost 10,000 euros. The study has been published in the journal Clinical Infectious Diseases and presented at the European Congress of Microbiology and Infectious Diseases held in Lisbon.
22/02/2022 - Covid-19
Dr. Esther Barreiro is the editor of the book 'Physiopathology of COVID-19 in different organs and systems', published by Elsevier. It is a work and study manual for people interested in learning more about this disease. The experts from Hospital del Mar have played a leading role in the new publication by Elsevier, Physiopathology of COVID-19 in different organs and systems, the first manual that analyses, with the help of various specialists, the effects caused by SARS-CoV-2, its mechanisms of infection, treatment, and sequelae. Dr. Esther Barreiro, consultant physician in the Pneumology Department at Hospital del Mar, researcher at the Hospital del Mar Medical Research Institute (IMIM), and associate professor at Pompeu Fabra University, is the editor.
21/01/2022 - Covid-19
12% of patients admitted for COVID-19 who also suffer heart damage need to be readmitted or die within the first year after recovering from the disease. In contrast, this occurs in only 1% of those who do not suffer heart damage during the SARS-CoV-2 infection, according to a study published in the Journal of Clinical Medicine. These people have a baseline situation that is aggravated by previous pathologies such as high blood pressure, chronic renal failure and episodes of heart failure. The authors of the study recommend routine screening for heart damage markers in the blood of patients admitted for COVID-19 to be able to carefully monitor these problems in the long term. Patients who suffer heart damage during a COVID-19 infection are more likely to need to be readmitted to hospital or to die than those who survive the disease without suffering this. This has been revealed by a study led by researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the CIBER in Cardiovascular Diseases (CIBERCV), which has been published in the Journal of Clinical Medicine.
Més informació "Cardiac damage in COVID-19 patients is an indicator of poor long-term prognosis"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
